时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Non-small cell lung cancer (NSCLC) is predominantly diagnosed in older adults, many of whom present with multiple comorbidities and varying degrees of frailty.
方法
These factors complicate diagnostic investigations, treatment decisions, and outcomes.
核心结论
Limited real-world guidance exists on managing advanced NSCLC in patients with comorbidities and frailty.；To address this knowledge gap, a multidisciplinary panel of 10 United Kingdom (UK) experts, including six lung oncologists, two clinical nurse specialists, and two pharmacists, participated in two virtual workshops to identify key challenges and best…；Twenty-three draft consensus statements were developed based on discussion at the workshops, with a further two experts (one respiratory physician and one geriatrician) invited to draft and/or review the statements at that time.
局限
（原文未给出可直接抽取的对应表述）
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：功能结局（衰弱 / 肌少症）是临床转化最可及的终点，适合作为一期终点候选。 ｜ 价值分 1.8/5（★★☆☆☆）
全文来源
未取到全文 → 本卡为摘要级解读，未核验全文
原文题录
- 英文标题：Managing patients with advanced non-small cell lung cancer alongside complex comorbidities and frailty: A consensus statement and implications for the United Kingdom health system.
- 期刊与标识：Journal of geriatric oncology · PMID 42956446 · DOI 10.1016/j.jgo.2026.104651
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。